Published in Virology on November 05, 2010
C7L family of poxvirus host range genes inhibits antiviral activities induced by type I interferons and interferon regulatory factor 1. J Virol (2012) 1.05
Vaccinia virus A6 is essential for virion membrane biogenesis and localization of virion membrane proteins to sites of virion assembly. J Virol (2012) 0.93
An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies. Virology (2011) 0.91
Vaccinia virus virion membrane biogenesis protein A11 associates with viral membranes in a manner that requires the expression of another membrane biogenesis protein, A6. J Virol (2012) 0.91
Analysis of viral membranes formed in cells infected by a vaccinia virus L2-deletion mutant suggests their origin from the endoplasmic reticulum. J Virol (2012) 0.90
Direct formation of vaccinia virus membranes from the endoplasmic reticulum in the absence of the newly characterized L2-interacting protein A30.5. J Virol (2013) 0.90
Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein. J Virol (2014) 0.89
Analysis of the role of vaccinia virus H7 in virion membrane biogenesis with an H7-deletion mutant. J Virol (2013) 0.85
Structural and biochemical characterization of the vaccinia virus envelope protein D8 and its recognition by the antibody LA5. J Virol (2012) 0.84
Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol (2012) 0.82
Elimination of A-type inclusion formation enhances cowpox virus replication in mice: implications for orthopoxvirus evolution. Virology (2014) 0.79
Development of a Genus-Specific Antigen Capture ELISA for Orthopoxviruses - Target Selection and Optimized Screening. PLoS One (2016) 0.78
Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion. Vaccine (2011) 0.77
Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer. PLoS Pathog (2015) 0.75
Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox. J Virol (2016) 0.75
The Vaccinia Virus H3 Envelope Protein, a Major Target of Neutralizing Antibodies, Exhibits a Glycosyltransferase Fold and Binds UDP-Glucose. J Virol (2016) 0.75
Deletion of the Vaccinia Virus I2 Protein Interrupts Virion Morphogenesis, Leading to Retention of the Scaffold Protein and Mislocalization of Membrane-Associated Entry Proteins. J Virol (2017) 0.75
Duration of antiviral immunity after smallpox vaccination. Nat Med (2003) 7.39
Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol (2003) 5.51
A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol (2006) 4.52
The formation and function of extracellular enveloped vaccinia virus. J Gen Virol (2002) 4.14
Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A (2005) 3.59
Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med (2004) 3.43
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
In a nutshell: structure and assembly of the vaccinia virion. Adv Virus Res (2006) 3.17
Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. J Virol (1985) 3.06
Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus. J Virol (1979) 2.94
A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology (1995) 2.82
Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature (1988) 2.63
Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells. Proc Natl Acad Sci U S A (1995) 2.45
Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity (2008) 2.43
Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol (1999) 2.43
Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol (2005) 2.18
DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology (2000) 2.16
Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology (1999) 2.15
Production, specificity, and functionality of monoclonal antibodies to specific peptide-major histocompatibility complex class II complexes formed by processing of exogenous protein. Proc Natl Acad Sci U S A (1997) 2.13
HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci U S A (2005) 2.11
Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics (2007) 2.10
The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J Virol (1998) 2.05
The multistep proteolytic maturation pathway utilized by vaccinia virus P4a protein: a degenerate conserved cleavage motif within core proteins. Virology (1991) 1.86
Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol (2008) 1.77
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol (2007) 1.77
Neutralizing epitope on penetration protein of vaccinia virus. Virology (1996) 1.75
Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol (2006) 1.66
Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med (2006) 1.64
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology (2004) 1.58
Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol (2008) 1.49
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Biogenesis of vaccinia: carbohydrate of the hemagglutinin molecules. Virology (1981) 1.39
Correlates of protective immunity in poxvirus infection: where does antibody stand? Immunol Cell Biol (2007) 1.33
Identification from diverse mammalian poxviruses of host-range regulatory genes functioning equivalently to vaccinia virus C7L. Virology (2007) 1.29
Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin. Virology (2005) 1.26
Investigation of structural and functional motifs within the vaccinia virus A14 phosphoprotein, an essential component of the virion membrane. J Virol (2003) 1.26
Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology (2006) 1.21
Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J Immunol (2006) 1.21
Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect (2005) 1.20
Intracellular localization of vaccinia virus extracellular enveloped virus envelope proteins individually expressed using a Semliki Forest virus replicon. J Virol (2000) 1.12
Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J Gen Virol (2005) 1.12
Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology (2008) 1.05
Epitope mosaic on the surface proteins of orthopoxviruses. Virology (1988) 1.05
Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol (2009) 1.03
Identification of antigenic determinants by polyclonal and hybridoma antibodies induced during the course of infection by vaccinia virus. Virology (1986) 0.98
Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein. J Gen Virol (2009) 0.86
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Activation of innate immune antiviral responses by Nod2. Nat Immunol (2009) 4.19
Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A (2003) 4.00
Prevention of Chlamydia-induced infertility by inhibition of local caspase activity. J Infect Dis (2013) 2.79
Hemorrhagic fever caused by a novel Bunyavirus in China: pathogenesis and correlates of fatal outcome. Clin Infect Dis (2011) 2.34
Hemorrhagic fever caused by a novel tick-borne Bunyavirus in Huaiyangshan, China. Zhonghua Liu Xing Bing Xue Za Zhi (2011) 2.15
Genome-wide identification of Chlamydia trachomatis antigens associated with trachomatous trichiasis. Invest Ophthalmol Vis Sci (2012) 2.13
Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One (2008) 2.12
In vivo whole animal body imaging reveals colonization of Chlamydia muridarum to the lower genital tract at early stages of infection. Mol Imaging Biol (2014) 2.03
Activation of Raf/MEK/ERK/cPLA2 signaling pathway is essential for chlamydial acquisition of host glycerophospholipids. J Biol Chem (2003) 1.97
The chlamydial plasmid-encoded protein pgp3 is secreted into the cytosol of Chlamydia-infected cells. Infect Immun (2008) 1.97
Caspase-1 contributes to Chlamydia trachomatis-induced upper urogenital tract inflammatory pathologies without affecting the course of infection. Infect Immun (2007) 1.85
Characterization of fifty putative inclusion membrane proteins encoded in the Chlamydia trachomatis genome. Infect Immun (2008) 1.77
Novel method for high-throughput phenotyping of sleep in mice. Physiol Genomics (2006) 1.77
Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet (2005) 1.72
A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J Exp Med (2011) 1.70
Profiling of human antibody responses to Chlamydia trachomatis urogenital tract infection using microplates arrayed with 156 chlamydial fusion proteins. Infect Immun (2006) 1.67
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest (2015) 1.67
EV71: an emerging infectious disease vaccine target in the Far East? Vaccine (2010) 1.65
Cleavage of host keratin 8 by a Chlamydia-secreted protease. Infect Immun (2004) 1.64
Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology (2008) 1.64
Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun (2006) 1.63
The secreted protease factor CPAF is responsible for degrading pro-apoptotic BH3-only proteins in Chlamydia trachomatis-infected cells. J Biol Chem (2006) 1.60
Chlamydia-infected cells continue to undergo mitosis and resist induction of apoptosis. Infect Immun (2004) 1.60
Human antibody responses to a Chlamydia-secreted protease factor. Infect Immun (2004) 1.59
Improved peptide elution time prediction for reversed-phase liquid chromatography-MS by incorporating peptide sequence information. Anal Chem (2006) 1.59
A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans. J Immunol (2010) 1.55
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A (2006) 1.52
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.51
Reducing exposure to avian influenza H7N9. Lancet (2013) 1.50
Mice deficient in MyD88 Develop a Th2-dominant response and severe pathology in the upper genital tract following Chlamydia muridarum infection. J Immunol (2010) 1.49
A novel genotype H9N2 influenza virus possessing human H5N1 internal genomes has been circulating in poultry in eastern China since 1998. J Virol (2009) 1.49
Degradation of the proapoptotic proteins Bik, Puma, and Bim with Bcl-2 domain 3 homology in Chlamydia trachomatis-infected cells. Infect Immun (2005) 1.48
Tumor necrosis factor alpha production from CD8+ T cells mediates oviduct pathological sequelae following primary genital Chlamydia muridarum infection. Infect Immun (2011) 1.48
The hypothetical protein CT813 is localized in the Chlamydia trachomatis inclusion membrane and is immunogenic in women urogenitally infected with C. trachomatis. Infect Immun (2006) 1.47
Genetic analysis of the promoter region of the GATA4 gene in patients with ventricular septal defects. Transl Res (2011) 1.45
LMP2/LMP7 gene variant: a risk factor for intestinal Mycobacterium tuberculosis infection in the Chinese population. J Gastroenterol Hepatol (2011) 1.45
AMP-activated protein kinase contributes to UV- and H2O2-induced apoptosis in human skin keratinocytes. J Biol Chem (2008) 1.44
A BAC-based physical map of the chicken genome. Genome Res (2003) 1.43
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.43
Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology (2007) 1.42
CT694 and pgp3 as serological tools for monitoring trachoma programs. PLoS Negl Trop Dis (2012) 1.40
MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting β-catenin. Biochem Biophys Res Commun (2012) 1.40
Quantitative and trajectory analysis of movement trajectories in supplementary motor area seizures of frontal lobe epilepsy. Epilepsy Behav (2008) 1.39
A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum. J Immunol (2009) 1.39
Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine (2010) 1.38
A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine (2004) 1.38
Intracellular interleukin-1alpha mediates interleukin-8 production induced by Chlamydia trachomatis infection via a mechanism independent of type I interleukin-1 receptor. Infect Immun (2007) 1.37
Collective dipole oscillations of a spin-orbit coupled Bose-Einstein condensate. Phys Rev Lett (2012) 1.37
Cleavage-dependent activation of a chlamydia-secreted protease. Mol Microbiol (2004) 1.37
Chlamydia trachomatis infection inhibits both Bax and Bak activation induced by staurosporine. Infect Immun (2004) 1.36
Structural basis for activation and inhibition of the secreted chlamydia protease CPAF. Cell Host Microbe (2008) 1.36
Chlamydia trachomatis pulmonary infection induces greater inflammatory pathology in immunoglobulin A deficient mice. Cell Immunol (2004) 1.34
Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol (2008) 1.34
Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines (2009) 1.34
Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine (2009) 1.32
Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest (2008) 1.32
Characterization of Chlamydia trachomatis plasmid-encoded open reading frames. J Bacteriol (2013) 1.31
Recycling of Shiga toxin 2 genes in sorbitol-fermenting enterohemorrhagic Escherichia coli O157:NM. Appl Environ Microbiol (2007) 1.31
Bone marrow mononuclear cells promote proliferation of endogenous neural stem cells through vascular niches after cerebral infarction. Stem Cells (2010) 1.30
Live imaging reveals differing roles of macrophages and neutrophils during zebrafish tail fin regeneration. J Biol Chem (2012) 1.30
Identification from diverse mammalian poxviruses of host-range regulatory genes functioning equivalently to vaccinia virus C7L. Virology (2007) 1.29
Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine (2007) 1.28
Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect Immun (2006) 1.27
Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem (2012) 1.27
Production of a proteolytically active protein, chlamydial protease/proteasome-like activity factor, by five different Chlamydia species. Infect Immun (2005) 1.26
Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol (2005) 1.26
Transplantation of human bone marrow-derived mesenchymal stem cells promotes behavioral recovery and endogenous neurogenesis after cerebral ischemia in rats. Brain Res (2010) 1.26
Intramolecular dimerization is required for the chlamydia-secreted protease CPAF to degrade host transcriptional factors. Infect Immun (2004) 1.25
Inhibition of host cell cytokinesis by Chlamydia trachomatis infection. J Infect (2003) 1.24
Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. J Virol (2009) 1.24
SIRT1 confers protection against UVB- and H2O2-induced cell death via modulation of p53 and JNK in cultured skin keratinocytes. J Cell Mol Med (2008) 1.24
Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine (2005) 1.23
Stability of quantum dots in live cells. Nat Chem (2011) 1.22
Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol (2005) 1.21
Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology (2006) 1.21
Genome-wide identification of Chlamydia trachomatis antigens associated with tubal factor infertility. Fertil Steril (2011) 1.21
Inhibition of proteolytic activity of a chlamydial proteasome/protease-like activity factor by antibodies from humans infected with Chlamydia trachomatis. Infect Immun (2005) 1.21
Divergence and mosaicism among virulent soil phages of the Burkholderia cepacia complex. J Bacteriol (2006) 1.20
Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol (2006) 1.20